Research analysts covering CytoMed Therapeutics.
Recent press releases and 8-K filings for GDTC.
CytoMed Therapeutics Announces Clinical Trial Collaboration in Malaysia
GDTC
New Projects/Investments
- On December 8, 2025, CytoMed Therapeutics Limited (GDTC) announced a Memorandum of Understanding (MOU) with Universiti Malaya Medical Centre (UMMC) to establish a multi-site, first-in-human Phase I clinical trial in Malaysia.
- This trial will evaluate the safety and efficacy of CytoMed's allogeneic unmodified Gamma Delta (γδ) T cells ("CTM-GDT") for no-option cancer patients.
- The company emphasizes its allogeneic technology as more cost-effective and accessible than autologous therapies, utilizing donor-derived γδ T cells that do not trigger immune rejection.
- This initiative complements CytoMed’s ongoing first-in-human Phase I CAR T clinical trial in Singapore.
Dec 8, 2025, 1:00 PM
CytoMed Therapeutics Completes Acquisition of T Cell Technology
GDTC
M&A
New Projects/Investments
- CytoMed Therapeutics Limited (GDTC) completed the acquisition of the allogeneic gamma delta T cell technology (TCB-002) from TC BioPharm Limited on November 18, 2025.
- This acquisition is intended to repurpose the technology to treat cancers in China and India, leveraging new Chinese regulations (State Council Decree No. 818) that liberalize the clinical use of cellular products.
- The acquired TCB-002 technology has previously completed a Phase I clinical trial in Europe and was granted orphan drug designation by the U.S. FDA for Acute Myeloid Leukemia.
- CytoMed is in discussions with partners to develop a non-cell-based manufacturing method for China, which would be more easily scalable and cost-effective due to local regulations.
- The company does not expect an immediate material financial impact from this acquisition and related arrangements.
Nov 18, 2025, 1:00 PM
CytoMed Therapeutics Submits Cash Bid for TC BioPharm Assets
GDTC
M&A
New Projects/Investments
Takeover Bid
- CytoMed Therapeutics Limited (GDTC) has submitted a cash bid for an undisclosed sum to acquire potentially synergistic assets of TC BioPharm Limited (TCBL), which entered administration on October 2, 2025.
- The proposed acquisition aims to strengthen CytoMed's expertise in allogeneic cell therapies for cancer treatment, accelerate its commercialization timeline, and advance its mission to provide affordable therapeutic options.
- This marks CytoMed's second acquisition within approximately one year, following the asset acquisition of a licensed cord blood bank in Malaysia on October 3, 2024.
- The proposed acquisition will be funded by internal resources.
Oct 14, 2025, 12:00 PM
CytoMed Therapeutics Announces Publication of Collaborative Research on AML Treatment
GDTC
New Projects/Investments
- CytoMed Therapeutics Limited announced on October 2, 2025, the publication of collaborative research with The University of Texas, MD Anderson Cancer Center, demonstrating the potential of the Company’s Allogeneic γδ T Cells (CTM-GDT) to treat Acute Myeloid Leukemia (AML).
- The study, titled "Donor-Derived Vγ9Vδ2 T Cells for Acute Myeloid Leukemia: A Promising 'off-the-shelf' Immunotherapy Approach", provides the rationale for further clinical study of allogeneic donor-derived γδ T cells in treating AML and other cancers.
- CytoMed plans to advance this γδ T cell-based product into clinical trials in Southeast Asia, following its leading product, CAR-γδ T cells (CTM-N2D), which is currently undergoing a Phase 1 clinical trial in Singapore.
Oct 2, 2025, 11:00 AM
CytoMed Therapeutics Ltd Reports Increased Net Loss and Initiates ATM Sales Agreement in Q2 2025
GDTC
Earnings
New Projects/Investments
- For the six months ended June 30, 2025, CytoMed Therapeutics Ltd reported a net loss of S$2,245,828 (U.S.$1,765,727), significantly higher than S$1,088,543 in the prior year period, while generating its first revenue of S$155,887 (U.S.$122,562) mainly from private blood banking services.
- The company's cash and bank balances declined to S$2,854,958 (U.S.$2,244,640) as of June 30, 2025, from S$4,970,367 at December 31, 2024, with net cash used in operating activities totaling S$1,599,164 (U.S.$1,257,303) for the six months ended June 30, 2025.
- CytoMed Therapeutics Ltd is advancing its lead product candidate, CTM-N2D, with the Phase 1 clinical trial completing dose level 1 in June 2025 and dose level 2 currently underway.
- To bolster its financial position, the company entered into an ATM Sales Agreement on August 18, 2025, allowing it to offer and sell ordinary shares up to an aggregate of U.S.$4.30 million.
Sep 30, 2025, 11:00 AM
CytoMed Therapeutics Expands into Cord Blood-Derived Therapeutics and Reorganizes Structure
GDTC
New Projects/Investments
M&A
Product Launch
- CytoMed Therapeutics Limited (GDTC) announced a strategic reorganization to create a new cord blood-derived biotech, LongevityBank Pte Ltd, after successfully expanding clinical-scale natural killer (NK) cells from cord blood units.
- This initiative builds on the October 3, 2024, asset acquisition of a licensed cord blood bank in Malaysia, IPSC Depository Sdn Bhd, which LongevityBank will leverage to focus on autologous therapies and re-start its cord blood banking business.
- Management and EP Capital Inc. intend to invest up to US$500,000 in LongevityBank's equity to purchase new equipment and refurbish its laboratory, with plans to eventually spin off LongevityBank as a standalone biopharmaceutical company.
Aug 28, 2025, 1:10 PM
Quarterly earnings call transcripts for CytoMed Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more